Arteris, Inc. (NASDAQ:AIP – Get Free Report) CEO K Charles Janac sold 17,856 shares of Arteris stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $10.12, for a total value of $180,702.72. Following the completion of the transaction, the chief executive officer now owns 10,287,435 shares in the company, valued at $104,108,842.20. The trade was a 0.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
K Charles Janac also recently made the following trade(s):
- On Tuesday, December 3rd, K Charles Janac sold 1,242 shares of Arteris stock. The shares were sold at an average price of $8.58, for a total transaction of $10,656.36.
- On Wednesday, October 2nd, K Charles Janac sold 5,520 shares of Arteris stock. The stock was sold at an average price of $7.18, for a total value of $39,633.60.
Arteris Stock Up 1.5 %
Arteris stock opened at $10.29 on Friday. Arteris, Inc. has a twelve month low of $4.83 and a twelve month high of $10.60. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market cap of $413.45 million, a PE ratio of -10.72 and a beta of 1.25. The firm’s 50 day moving average price is $8.00 and its two-hundred day moving average price is $7.83.
Hedge Funds Weigh In On Arteris
Wall Street Analysts Forecast Growth
Separately, Rosenblatt Securities reissued a “buy” rating and issued a $15.00 price objective on shares of Arteris in a research note on Wednesday, November 6th.
Get Our Latest Analysis on Arteris
Arteris Company Profile
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.
Recommended Stories
- Five stocks we like better than Arteris
- Health Care Stocks Explained: Why You Might Want to Invest
- Texas Instruments: The Old-School Tech Titan Still Delivering
- The 3 Best Blue-Chip Stocks to Buy Now
- GRAIL: Biotech Stock Targeting $100B Cancer Market
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 12/9 – 12/13
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.